Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Akari Therapeutics, Plc (AKTX)

0.2505   -0.005 (-2.07%) 03-24 16:00
Open: 0.27 Pre. Close: 0.2558
High: 0.27 Low: 0.2363
Volume: 108,454 Market Cap: 19(M)

Technical analysis

as of: 2023-03-24 4:23:54 PM
Stoxline posted a BUY today, same as yesterday. Upward movement continues.
Target: Six months: 0.43     One year: 0.54
Support: Support1: 0.21    Support2: 0.18
Resistance: Resistance1: 0.37    Resistance2: 0.46
Pivot: 0.27
Moving Average: MA(5): 0.24     MA(20): 0.28
MA(100): 0.45     MA(250): 0.78
MACD: MACD(12,26): -0.1     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 23     %D(3): 19.2
RSI: RSI(14): 31.4
52-week: High: 1.61  Low: 0.21
Average Vol(K): 3-Month: 131 (K)  10-Days: 146 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ AKTX ] has closed above bottom band by 30.2%. Bollinger Bands are 11.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 0.27 - 0.27 0.27 - 0.27
Low: 0.23 - 0.23 0.23 - 0.24
Close: 0.25 - 0.25 0.25 - 0.25

Company Description

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid. Akari Therapeutics, Plc is based in London, the United Kingdom.

Headline News

Wed, 15 Feb 2023
Akari Therapeutics Announces Pre-Clinical Development Progress ... - GlobeNewswire

Tue, 22 Nov 2022
Akari Therapeutics to Participate in the Ophthalmology Day at BTIG - Yahoo Finance

Thu, 10 Nov 2022
Akari Therapeutics Granted FDA Rare Pediatric Disease ... - GlobeNewswire

Tue, 08 Nov 2022
Akari Therapeutics Announces the Appointment of John F. Neylan ... - GlobeNewswire

Tue, 20 Sep 2022
Will Akari Therapeutics (NASDAQ:AKTX) Spend Its Cash Wisely? - Simply Wall St

Mon, 12 Sep 2022
Akari Therapeutics Announces $12.75 Million Registered Direct ... - GlobeNewswire

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 74 (M)
Shares Float 44 (M)
% Held by Insiders 7.5 (%)
% Held by Institutions 12.1 (%)
Shares Short 92 (K)
Shares Short P.Month 94 (K)

Stock Financials

EPS -0.31
EPS Est Next Qtl -0.67
EPS Est This Year -2.36
EPS Est Next Year -3.11
Book Value (p.s.) 0.14
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -142
Return on Equity (ttm) -365.1
Qtrly Rev. Growth 0
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -0.25
Qtrly Earnings Growth 0
Operating Cash Flow -20 (M)
Levered Free Cash Flow -14 (M)

Stock Valuations

PE Ratio -0.84
PEG Ratio 0
Price to Book value 1.78
Price to Sales 0
Price to Cash Flow -0.93

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.